Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15925142 | 0.88 | KCNH2 (0.37) | KCNH2 | |
| SCHEMBL16260496 | 0.88 | KCNH2 (0.35) | KCNH2 | |
| SCHEMBL10202969 | 0.85 | KCNH2 (0.43) | KCNH2CACNA1I | |
| SCHEMBL26748986 | 0.85 | S1PR1 (0.37) | KCNH2 | |
| SCHEMBL13656344 | 0.79 | KCNH2 (0.39) | KCNH2CACNA1I | |
| SCHEMBL15925043 | 0.78 | KCNH2 (0.32) | KCNH2 | |
| SCHEMBL12665794 | 0.78 | — | — | |
| SCHEMBL27432388 | 0.78 | CYP2D6 (0.41) | KCNH2CACNA1I | |
| SCHEMBL9944465 | 0.78 | KCNH2 (0.38) | KCNH2 | |
| SCHEMBL18860252 | 0.78 | KCNH2 (0.35) | KCNH2CACNA1I |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170015631-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2017-01-19 | — | — | US | disclosed |
| US-9394257-B2 | PKM2 modulators and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150344436-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015631-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | KCNH2 1007/4885CACNA1I 3945/4885 |
| US-20150344436-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | KCNH2 1007/4885CACNA1I 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.